Kanonji Institute, The Research Foundation for Microbial Diseases of Osaka University, Kanonji, Kagawa, Japan.
Viral Immunol. 2012 Oct;25(5):433-9. doi: 10.1089/vim.2012.0026. Epub 2012 Sep 17.
Here we examined whether polymeric IgA (pIgA) and monomeric IgA (mIgA) antibodies differ in their ability to neutralize drift viruses within the same subtype. We used an IgA monoclonal antibody (mAb; H1-21) against influenza virus strain A/Hiroshima/52/2005 (A/Hiroshima; H3N2). The mAb was obtained after immunizing mice mucosally with a split-virion (SV) vaccine. The mAb contained both mIgA and pIgA forms. It reacted with the homologous virus and cross-reacted with drift viruses A/New York/55/2004 (H3N2) and A/Wyoming/3/2003 (H3N2) in hemagglutinin-inhibition (HI) and neutralizing Ab assays. The mAb also cross-reacted with A/Panama/2007/99 (H3N2) in an ELISA. We separated the mAb into pIgA and mIgA fractions by gel filtration, and then tested them for neutralizing Ab activity. The neutralizing activity for the A/Hiroshima/52/2005, A/New York/55/2004, and A/Wyoming/3/2003 viruses was lower for the mIgA than the pIgA fraction. However, the neutralizing efficiency for drift variants relative to that for the homotype did not differ between pIgA and mIgA, and pIgA only neutralized variants that could also be neutralized by mIgA. These results suggest that the polymerization of IgA enhances its antiviral immune responses, but does not increase the number of influenza virus strains neutralized by the IgA.
在这里,我们研究了同一种亚型内的漂移病毒,聚合 IgA(pIgA)和单体 IgA(mIgA)抗体在中和能力上是否存在差异。我们使用了针对流感病毒株 A/Hiroshima/52/2005(A/Hiroshima;H3N2)的 IgA 单克隆抗体(mAb;H1-21)。该 mAb 是通过黏膜免疫用 SV 疫苗免疫小鼠获得的。该 mAb 包含 mIgA 和 pIgA 两种形式。它与同源病毒反应,并在血凝抑制(HI)和中和抗体测定中与漂移病毒 A/New York/55/2004(H3N2)和 A/Wyoming/3/2003(H3N2)发生交叉反应。该 mAb 在 ELISA 中也与 A/Panama/2007/99(H3N2)发生交叉反应。我们通过凝胶过滤将 mAb 分离为 pIgA 和 mIgA 部分,然后测试它们的中和抗体活性。与 pIgA 部分相比,mIgA 对 A/Hiroshima/52/2005、A/New York/55/2004 和 A/Wyoming/3/2003 病毒的中和活性较低。然而,漂移变体相对于同型的中和效率在 pIgA 和 mIgA 之间没有差异,并且 pIgA 仅中和可被 mIgA 中和的变体。这些结果表明,IgA 的聚合增强了其抗病毒免疫反应,但不会增加被 IgA 中和的流感病毒株的数量。